Application techniques of a novel hemostat in cardiac operations: HEMOBLAST.
cardiac
collagen
hemostat
hemostatic powder
thrombin
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
28
7
2019
medline:
11
2
2020
entrez:
27
7
2019
Statut:
ppublish
Résumé
Postoperative bleeding complications are associated with less favorable outcomes in cardiac surgery and contribute to excessive overall healthcare costs. HEMOBLAST (Biom'up, Lyon, France) (HB) is a novel ready-to-use hemostatic powder that consists of porcine collagen, bovine chondroitin sulfate, and human pooled plasma thrombin that may help reduce surgical bleeding. The aim of this study was to describe the techniques of application for this new combination powder-based hemostat, HB, and demonstrate its use employing photographs of application methods during cardiac procedures. The initial 24 procedures in which HB was used at our institution included: left ventricular assist device (LVAD) insertions, lung transplants, heart transplants, aortic valve replacements, coronary artery bypass grafting, and mitral valve repair. Hemostasis was achieved in all cases and there were no instances of mediastinitis, sternal infections, allergic reactions, or 30-day mortality. This report describes the best methods of application of HB including use for treatment of mediastinal bleeding in a re-operative procedure in a patient on antiplatelet agents and sternal bleeding during an LVAD insertion. Proper application can facilitate excellent hemostasis using this powder. HB is a novel powder-based multiple component hemostatic agent that promotes focal or large area hemostasis. We have presented the techniques of use that are important to the successful application of HB to facilitate hemostasis.
Sections du résumé
BACKGROUND
BACKGROUND
Postoperative bleeding complications are associated with less favorable outcomes in cardiac surgery and contribute to excessive overall healthcare costs. HEMOBLAST (Biom'up, Lyon, France) (HB) is a novel ready-to-use hemostatic powder that consists of porcine collagen, bovine chondroitin sulfate, and human pooled plasma thrombin that may help reduce surgical bleeding.
AIMS
OBJECTIVE
The aim of this study was to describe the techniques of application for this new combination powder-based hemostat, HB, and demonstrate its use employing photographs of application methods during cardiac procedures.
MATERIALS AND METHODS
METHODS
The initial 24 procedures in which HB was used at our institution included: left ventricular assist device (LVAD) insertions, lung transplants, heart transplants, aortic valve replacements, coronary artery bypass grafting, and mitral valve repair.
RESULTS
RESULTS
Hemostasis was achieved in all cases and there were no instances of mediastinitis, sternal infections, allergic reactions, or 30-day mortality.
DISCUSSION
CONCLUSIONS
This report describes the best methods of application of HB including use for treatment of mediastinal bleeding in a re-operative procedure in a patient on antiplatelet agents and sternal bleeding during an LVAD insertion. Proper application can facilitate excellent hemostasis using this powder.
CONCLUSION
CONCLUSIONS
HB is a novel powder-based multiple component hemostatic agent that promotes focal or large area hemostasis. We have presented the techniques of use that are important to the successful application of HB to facilitate hemostasis.
Identifiants
pubmed: 31348840
doi: 10.1111/jocs.14171
pmc: PMC6773212
doi:
Substances chimiques
Hemostatics
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
849-853Subventions
Organisme : Biom'up, Lyon, France
Informations de copyright
© 2019 The Authors. Journal of Cardiac Surgery Published by Wiley Periodicals, Inc.
Références
Blood. 2009 Apr 9;113(15):3406-17
pubmed: 19188662
J Cardiothorac Surg. 2014 Aug 02;9:134
pubmed: 25085116
J Med Econ. 2018 Mar;21(3):273-281
pubmed: 29096598
J Cardiothorac Surg. 2013 Mar 26;8:54
pubmed: 23531208
Crit Care Med. 2006 Jun;34(6):1608-16
pubmed: 16607235
J Biomed Mater Res. 2001;58(5):545-55
pubmed: 11505430
J Thorac Cardiovasc Surg. 2009 Sep;138(3):687-93
pubmed: 19698857
J Card Surg. 2019 Jan;34(1):50-62
pubmed: 30629770
Ann Thorac Cardiovasc Surg. 2001 Dec;7(6):352-7
pubmed: 11888475
J Card Surg. 2019 Sep;34(9):849-853
pubmed: 31348840
Ann Thorac Surg. 2009 Nov;88(5):1520-6
pubmed: 19853105